Prolexys Pharmaceuticals Raises $20M
Salt Lake City-based Prolexys Pharmaceuticals announced Thursday that it has raised $20M in a Series A1 funding round. The round was led by Friedli Corporate Finance, as well as Peter Friedli, chairman of Prolexys. Prolexys is developing a novel small molecule drug targeted at treating colon, lung, pancreatic, and ovarian cancer. Prolexys Pharmaceuticals said it currently has a compound in Phase 1 studies.
posted on Thursday, November 6, 2008 (Link to more information)
Related companies:
Prolexys Pharmaceuticals
Related stories:
> Recursion Pharmaceuticals Raises $60M
> Inflabloc Raises $6M
> LigoCyte Pharmaceuticals Raises $28M
> Tolero Pharmaceuticals Finds $14.2M
> N30 Pharmaceuticals Names New CEO
Techrockies.com Home